Solara Active Pharma Sciences Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Poorvank Purohit
Chief executive officer
₹39.8m
Total compensation
| CEO salary percentage | 72.9% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More
Sep 13
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce
Jul 20Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
May 11Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump
Apr 19Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely
Feb 23Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce
Jan 04Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price
May 12Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Nov 08Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Aug 03Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₹5b |
| Jun 30 2024 | n/a | n/a | -₹6b |
| Mar 31 2024 | ₹40m | ₹29m | -₹6b |
| Dec 31 2023 | n/a | n/a | -₹3b |
| Sep 30 2023 | n/a | n/a | -₹325m |
| Jun 30 2023 | n/a | n/a | -₹253m |
| Mar 31 2023 | ₹5m | n/a | -₹222m |
Compensation vs Market: Poorvank's total compensation ($USD468.13K) is above average for companies of similar size in the Indian market ($USD267.88K).
Compensation vs Earnings: Poorvank's compensation has increased whilst the company is unprofitable.
CEO
Poorvank Purohit (45 yo)
1.8yrs
Tenure
₹39,800,000
Compensation
Mr. Poorvank Purohit serves as Chief Executive Officer of Solara Active Pharma Sciences Limited since February 03, 2023 and serves as its Director & Managing Director since July 2023. He started his career...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.8yrs | ₹39.80m | no data | |
| Chief Financial Officer | less than a year | ₹700.00k | no data | |
| COO & Executive Director | 2.3yrs | ₹3.80m | no data | |
| Company Secretary | 6.8yrs | ₹4.80m | no data | |
| Founder & Non-Executive Director | no data | no data | 5.71% ₹ 1.9b | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Chief Quality Officer | no data | no data | no data |
1.8yrs
Average Tenure
Experienced Management: SOLARA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.4yrs | ₹39.80m | no data | |
| COO & Executive Director | less than a year | ₹3.80m | no data | |
| Founder & Non-Executive Director | 3.3yrs | no data | 5.71% ₹ 1.9b | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Director | 6.7yrs | ₹1.50m | no data | |
| Independent Chairman | 6.7yrs | ₹1.50m | 0.010% ₹ 3.4m | |
| Independent Director | 1.1yrs | ₹200.00k | no data | |
| Non-Executive Non-Independent Director | 3.3yrs | no data | no data | |
| Independent Director | 1.1yrs | ₹400.00k | no data |
1.4yrs
Average Tenure
57yo
Average Age
Experienced Board: SOLARA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 02:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solara Active Pharma Sciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Rishabh Kale | Indsec Securities & Finance Ltd. |